Pharma Dro E 10ml/200mg Drostanolon Enanthate

PHARMA DRO E 200 is the brand name for drostanolone enanthate 200 mg/ml. It is formulated to deliver an extended release of drostanolone without the frequent pin schedule of its shorter cousin. The product has the same effects as drostanolone propionate, but with a longer half-life — around 4.5–5 days. That makes it well suited to longer cycles, where the aim is lean, high-quality muscle fullness and a dense look, without the excess subcutaneous water that often shows up with long esters. It stacks neatly with long-acting testosterone and trenbolone esters (PHARMA TEST E 300, E 500, C 250; PHARMA TREN E 200, H 100).

Masterone

Drostanolone was first described in 1959; it was developed by Syntex and reached the market a decade later, in 1970, under the trade name Masteron.

Drostanolone is an injectable anabolic steroid, a derivative of dihydrotestosterone (DHT). Medical literature describes it as a strong anabolic with anti-oestrogenic traits. The FDA approved drostanolone for the treatment of inoperable breast cancer in climacteric women, as did regulators across many other parts of the world.

Biologically, Masteron behaves much like DHT — being a derivative of it. And its effects come through most clearly during a cutting cycle. For those effects to really register, though, the individual needs to be genuinely lean to begin with. Drostanolone does not cause water retention and shows a mild diuretic effect, in a similar vein to stanozolol; this helps bring out density, relief and definition in the muscle. It allows the kind of muscle condition most physique athletes are chasing, in large part thanks to the lipolytic action of the compound. In practice, a drostanolone cycle can drop body fat by 5–7%. The compound is recommended for track-and-field athletes and bodybuilders who need to stay inside a particular weight class.

As a bulking agent, Masteron is rather weak. In theory the hormone could deliver mass gains comparable to Primobolan (which would not be dramatic either), provided the total dose is high enough. Even so, the relative size gain stays modest, and many other anabolic steroids suit this phase of supplementation far better. Masteron does not aromatise and is not oestrogenic — in fact, it shows anti-oestrogenic traits by binding to aromatase in place of other substrates. That is one reason it has been useful in treating breast cancer.

In short, drostanolone acts in a way very close to stanozolol, but without Winstrol’s familiar drawbacks. It does not raise tendon brittleness, does not dry out joint fluid, and does not hit blood cholesterol as hard as stanozolol does. If the choice for a cutting cycle comes down to drostanolone or stanozolol, drostanolone is the more sensible and safer option.